A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

Rexin-G is a replication-incompetent retroviral vector displaying a cryptic SIG-binding peptide for targeting abnormal Signature (SIG) proteins in tumors and encoding a dominant-negative human cyclin G1 construct. Herein we report on the safety and antitumor activity of escalating doses of Rexin-G i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Sant P., Bruckner, Howard, Morse, Michael A., Assudani, Nupur, Hall, Frederick L., Gordon, Erlinda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348982/
https://www.ncbi.nlm.nih.gov/pubmed/30705966
http://dx.doi.org/10.1016/j.omto.2018.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348982/
https://www.ncbi.nlm.nih.gov/pubmed/30705966
http://dx.doi.org/10.1016/j.omto.2018.12.005

Ejemplares similares